aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

Rhea-AI Summary

aTyr Pharma, Inc. (Nasdaq: LIFE) has announced that it will report its third quarter 2021 financial results and provide a corporate update after market close on November 10, 2021. A conference call and webcast will be held the same day at 5:00 pm EST to discuss the results and operational updates. aTyr focuses on developing innovative medicines based on tRNA synthetases and is primarily advancing ATYR1923, which targets Neuropilin-2 to manage inflammatory lung diseases. For further details, visit aTyr's website.

Positive

• Focus on ATYR1923, a clinical-stage candidate targeting Neuropilin-2 for inflammatory lung diseases.
• Innovative approach based on newly discovered biological pathways related to tRNA synthetases.

Negative

• None.

Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2021 financial results and provide a corporate update after the market close on Wednesday, November 10, 2021. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Wednesday, November 10th @ 5:00 pm EST / 2:00 pm PST
Domestic: 844-358-9116
International: 209-905-5951
Conference ID: 9134928
Webcast: http://investors.atyrpharma.com/events-and-webcasts

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com 

FAQ

When will aTyr Pharma release its Q3 2021 financial results?

aTyr Pharma will report its third quarter 2021 financial results on November 10, 2021.

What time is the aTyr Pharma conference call on November 10, 2021?

The conference call is scheduled for 5:00 pm EST on November 10, 2021.

How can I access the conference call and webcast for aTyr Pharma's Q3 results?

You can access the conference call and webcast via the link on aTyr Pharma's investor relations website.

What is the main focus of aTyr Pharma's research?

aTyr Pharma focuses on the discovery and development of medicines based on tRNA synthetases and their pathways.

What is ATYR1923 and its purpose?

ATYR1923 is a clinical-stage product candidate aimed at down-regulating immune engagement in inflammatory lung diseases.